OKLAHOMA Health Care Authority

State of Oklahoma
SoonerCare

SoonerSelect | aetna

Ziihera® (zanidatamab-hrii) Prior Authorization Form

Member Name: _____ ***Date of Birth:*** _____ ***Member ID#:*** _____

Drug Information

☐ ***Physician billing (HCPCS code:*** _____ ***)*** ☐ ***Pharmacy billing (NDC:*** _____ ***)***

Dose: _____ ***Regimen:*** _____ ***Start Date (or date of next dose):*** _____

Billing Provider Information

Provider NPI: _____ ***Provider Name:*** _____

Provider Phone: _____ ***Provider Fax:*** _____

Prescriber Information

Prescriber NPI: _____ ***Prescriber Name:*** _____

Prescriber Phone: _____ ***Prescriber Fax:*** _____ ***Specialty:*** _____

Criteria

For Initial Authorization:

1. Please indicate the diagnosis and information:
   - ☐ **Biliary Tract Cancer (BTC)**
   - ☐ **Other:** _____
2. Is diagnosis unresectable or metastatic disease? Yes☐ No☐
3. Is disease human epidermal growth factor receptor 2 (HER2)-positive immunohistochemistry (IHC) 3+? Yes☐ No☐
4. Will Ziihera® be used for subsequent-line therapy? Yes☐ No☐
5. Will Ziihera® be used as a single agent? Yes☐ No☐

Additional Information: _____

For Continued Authorization:

1. Date of last dose: _____
2. Does patient have any evidence of progressive disease while on Ziihera® therapy? Yes☐ No☐
3. Has the member experienced any adverse drug reactions related to Ziihera® therapy? Yes☐ No☐

If yes, please specify adverse reactions: _____

Additional Information: _____

_____

Prescriber Signature: _____ **Date:** _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. *Failure to complete this form in full will result in processing delays.*

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.	CONFIDENTIALITY NOTICE *This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*